A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease.
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of
R1450 in patients with mild to moderate Alzheimer Disease. Patients will be randomized to
receive either R1450 or placebo by intravenous infusion for a total of 7 doses. The starting
dose will be escalated in subsequent cohorts of patients in an adaptive manner, after a
satisfactory assessment of safety, tolerability and pharmacokinetics of the previous dose.
The anticipated time on study treatment is 3-12 months, and the target sample size is <100
individuals.